GVIRF2023

项目负责人/主要研究者（最后，第一，中间）：Friede，Martin，H 项目总结（见说明）： 世界卫生组织（世卫组织）、比尔及梅林达·盖茨基金会（比尔及梅林达·盖茨基金会）和国家 过敏和传染病研究所（NIAID）签署了一份谅解备忘录， 全球疫苗行动计划（GVAP）。GVAP的开发是为了实现 疫苗合作十年，将免疫接种的全部益处扩大到所有人， 他们的出生地和居住地2020年，GVAP被IA 2030取代，其中全球 疫苗和免疫研究论坛（GVIRF）成为战略优先事项的一个关键组成部分7 （SP 7）.全球气候变化研究框架是一个科学论坛，它： 1)审查次级方案7研发议程的进展情况; 2)跟踪进展情况并讨论与优先疫苗研发有关的障碍; 3)确定建议研究和开发界在该领域采取的行动 疫苗和免疫研究; 4)为疫苗研究和免疫界之间建立联系创造机会。 第一届GVIRF于2014年3月14-16日在美国马里兰州贝塞斯达举行，第二届论坛于2014年3月15-17日举行。 2016年3月在南非约翰内斯堡举行，第三届论坛于2018年3月20日至22日在曼谷举行， 泰国第四届论坛原定于2020年3月在大韩民国首尔举行，但不得不取消 2021年2月举行了一次虚拟论坛。 面对面论坛定于2023年3月在大韩民国首尔举行。 该论坛由比尔及梅林达·盖茨基金会和NIAID共同主办，世卫组织提供捐助。 组织和举行会议的实物。 相关性（参见说明）： IVIR-AC主席将向SAGE报告IVIR-AC会议结论。与此同时，IVIR-AC 将审查专家咨询小组会议的成果和决定，以补充和支持 圣人 项目/履约现场（如果需要额外空间，请使用项目/履约现场格式页） 项目/绩效现场主要位置 组织名称：世界卫生组织 电话：480997543 街道1：Ave Appia 20 Street 2： 城市：日内瓦县：州： 邮政编码：1211 项目/绩效现场国会选区： 其他项目/绩效现场位置 组织名称：TBD DUNS： 第一街：第二街： 城市：首尔县：州： 国家：大韩民国邮政编码： 项目/绩效现场国会选区： PHS 398（修订版01/18批准至03/31/2020）OMB编号0925-0001 第2页：第2页 项目负责人/主要研究者（最后一名、第一名、中间名）： 高级/关键人员。参见说明。根据需要使用续页，以下列格式提供所需信息。 从项目总监/主要研究者开始。按字母顺序列出所有其他高级/关键人员，姓氏在前。 名称eRA Commons用户名组织在项目中的角色 马丁·弗里德 其他重要贡献者 名称组织在项目中的角色 人类胚胎干细胞的分类 如拟进行的项目涉及人类胚胎干细胞，请在以下列表中列出特定细胞系的注册号： https://grants.nih.gov/stem_cells/registry/current.htm.根据需要使用续页。 如果此时无法引用特定的行，请包括一个声明，说明将使用注册表中的一行。 细胞系 PHS 398（修订版01/18批准至03/31/2020）OMB编号0925-0001 第3页表格第2页-续 将下列各页依次编号 应用程序.不要使用后缀，如4a，4 b。

Program Director/Principal Investigator (Last, First, Middle): Friede, Martin, H PROJECT SUMMARY (See instructions): The World Health Organization (WHO), the Bill and Melinda Gates Foundation (BMGF) and the National Institute of Allergy and Infectious Diseases (NIAID) signed a MOU to collaborate on carrying out the objectives of the Global Vaccine Action Plan (GVAP). GVAP was developed to achieve the vision of the Decade of Vaccines of Collaboration in extending the full benefits of immunization to all people, regardless of where they were born or where they live. In 2020, GVAP was replaced by IA2030 where the Global Vaccine and Immunization Research Forum (GVIRF) became a key component of the Strategic Priorities 7 (SP7).The GVIRF serves as a scientific forum that: 1) review the SP7 R&D agenda progress; 2) track progress and discuss obstacles related to priority vaccine research and development; 3) identify actions recommended to be taken by the research and development community in the area of vaccines and immunization research, and; 4) create an opportunity for networking among the vaccine research and immunization community. The first GVIRF was held on 14-16 March 2014 in Bethesda, MD, USA, the 2nd Forum was held on 15-17 March 2016 in Johannesburg, South Africa and the 3rd Forum was held 20-22 March 2018 in Bangkok, Thailand. The 4th Forum was expected in Seoul, Republic of Korea, in March 2020, but had to be cancelled due to the Covid-19 pandemic and instead a virtual Forum took place in February 2021. An in-person forum is scheduled to take place in March 2023 in either Seoul, Republic of Korea. The Forum is co-sponsored by the Bill & Melinda Gates Foundation and NIAID, with contribution from WHO in kind for the organization and execution of the meeting. RELEVANCE (See instructions): IVIR-AC meeting conclusions will be reported by the IVIR-AC Chair to SAGE. At the same time IVIR-AC will review outcomes of SAGE meetings and decisions in order to complement and support the work of SAGE. PROJECT/PERFORMANCE SITE(S) (if additional space is needed, use Project/Performance Site Format Page) Project/Performance Site Primary Location Organizational Name: World Health Organization DUNS: 480997543 Street 1: Avenue Appia 20 Street 2: City: Geneva County: State: Province: Country: Switzerland Zip/Postal Code: 1211 Project/Performance Site Congressional Districts: Additional Project/Performance Site Location Organizational Name: TBD DUNS: Street 1: Street 2: City: Seoul County: State: Province: Country: Republic of Korea Zip/Postal Code: Project/Performance Site Congressional Districts: PHS 398 (Rev. 01/18 Approved Through 03/31/2020) OMB No. 0925-0001 Page 2 Form Page 2 Program Director/Principal Investigator (Last, First, Middle): SENIOR/KEY PERSONNEL. See instructions. Use continuation pages as needed to provide the required information in the format shown below. Start with Program Director(s)/Principal Investigator(s). List all other senior/key personnel in alphabetical order, last name first. Name eRA Commons User Name Organization Role on Project Friede, Martin WHO PI OTHER SIGNIFICANT CONTRIBUTORS Name Organization Role on Project Human Embryonic Stem Cells No Yes If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the following list: https://grants.nih.gov/stem_cells/registry/current.htm. Use continuation pages as needed. If a specific line cannot be referenced at this time, include a statement that one from the Registry will be used. Cell Line PHS 398 (Rev. 01/18 Approved Through 03/31/2020) OMB No. 0925-0001 Page 3 Form Page 2-continued Number the following pages consecutively throughout the application. Do not use suffixes such as 4a, 4b.